New ointment shows promise for restoring skin color in vitiligo

NCT ID NCT07181187

Completed Disease control Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial tested an ointment called MH004 in 156 people with non-segmental vitiligo, a condition that causes white patches on the skin. Participants applied the ointment to affected areas once or twice daily for 24 weeks. The study measured how much skin color returned, especially on the face. Results will show if this treatment is safe and effective enough to move to larger trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MH004 ointment (a topical medication applied to the skin)
What this could lead to: If successful, this could lead to a new topical treatment that helps restore skin color in people with vitiligo.
What could go wrong: This is an early-phase trial with only 156 participants. The ointment may not work better than a placebo, and long-term safety is not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VITILIGO are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

VITILIGO

Contacts and locations

Locations

Hangzhou Third People's Hospital

Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.